Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C33H44F2N2O3 |
Molecular Weight | 554.7109 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC(C)(C)CC[C@@]1(CC[C@]3(C)[C@]2([H])C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@]5([H])CC[C@@]34C)NC(=O)C(C)(F)F
InChI
InChIKey=RJCWBNBKOKFWNY-IDPLTSGASA-N
InChI=1S/C33H44F2N2O3/c1-27(2)11-13-33(37-26(40)32(8,34)35)14-12-31(7)24(20(33)17-27)21(38)15-23-29(5)16-19(18-36)25(39)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3,(H,37,40)/t20-,22-,24-,29-,30+,31+,33-/m0/s1
Molecular Formula | C33H44F2N2O3 |
Molecular Weight | 554.7109 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Omaveloxolone (RTA-408) is a synthetic triterpenoid exerting antioxidant inflammation modulator properties. It activates the transcription factor Nrf2 and inhibits NF-κB signaling. Omaveloxolone demonstrated antioxidant, anti-inflammatory, and anticancer activities. Reata Pharmaceuticals is developing omaveloxolone for the treatment of cancers, Friedreich's ataxia and mitochondrial disorders.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1075094 |
|||
Target ID: CHEMBL2094258 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25897966 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
300 mg 1 times / day multiple, oral Highest studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: Page: p.19 |
unhealthy, ADULT n = 10 Health Status: unhealthy Condition: Friedreich ataxia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 10 Sources: Page: p.19 |
Sample Use Guides
Phase 2 study investigated oral omaveloxolone (RTA-408) (2.5-300 mg capsules) in patients with Friedreich's Ataxia.
A Phase 1 healthy volunteer clinical study with RTA 408 Lotion (NCT02029716) consisted of 3 sequential parts. In Part A, RTA 408 Lotion (0.5 %, 1 %, and 3 %) and lotion vehicle were applied to individual 4-cm(2) sites twice daily for 14 days. In Parts B and C, separate groups of subjects had 3 % RTA 408 Lotion applied twice daily to a 100-cm(2) site for 14 days or a 500-cm(2) site for 28 days.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25897966
At low concentrations (≤ 25 nM), omaveloxolone (RTA-408) activated Nrf2 and suppressed nitric oxide and pro-inflammatory cytokine levels in interferon-γ-stimulated RAW 264.7 macrophage cells. At higher concentrations, RTA 408 inhibited tumor cell growth (GI50 = 260 ± 74 nM) and increased caspase activity in tumor cell lines, but not in normal primary human cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:19:22 GMT 2023
by
admin
on
Sat Dec 16 11:19:22 GMT 2023
|
Record UNII |
G69Z98951Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2080
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
||
|
FDA ORPHAN DRUG |
461214
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/18/2037
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
||
|
FDA ORPHAN DRUG |
461114
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
G69Z98951Q
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
PRIMARY | |||
|
CD-116
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
PRIMARY | |||
|
DB12513
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
PRIMARY | |||
|
10135
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
PRIMARY | |||
|
1474034-05-3
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
PRIMARY | |||
|
71811910
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
PRIMARY | |||
|
SUB179300
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL3707273
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
PRIMARY | |||
|
G69Z98951Q
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
PRIMARY | |||
|
DTXSID101138251
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
PRIMARY | |||
|
100000164733
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
PRIMARY | |||
|
C113443
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
PRIMARY | |||
|
RTA 408
Created by
admin on Sat Dec 16 11:19:22 GMT 2023 , Edited by admin on Sat Dec 16 11:19:22 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> ACTIVATOR |
|
||
|
TARGET -> INHIBITOR |
suppresses activity
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|